<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: December 3, 1998
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. ("the Company"), in a press release dated
December 3, 1998 and filed as Exhibit 99 hereto, announced that it has
received two patents by the United States Patent and Trademark Office. The
Company had previously announced that the Patent and Trademark Office issued
notices of allowance for the claims covered in these patents.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
<TABLE>
<S> <C>
99 Press release of the Company, dated December 3, 1998, announcing the
receipt of two patents by the United States Patent and Trademark Office.
</TABLE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
John Smolik, President
Date: December 8, 1998
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
No.
<S> <C>
99 Press release of the Company, dated December 3, 1998, announcing the
receipt of two patents by the United States Patent and Trademark
Office.
</TABLE>
<PAGE>
Exhibit 99
Photogen Technologies, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931
Voice: 423-769-4012
Fax: 423-769-4013
Internet: www.photogen.com
PHOTOGEN AWARDED PATENTS ON CORNERSTONE PHOTODYNAMIC THERAPY TECHNOLOGIES
PATENTS ANNOUNCED AS COMPANY BEGINS DEVELOPMENT OF TREATMENTS FOR
DISEASES OF THE EYE
KNOXVILLE, Tenn.--Dec. 3, 1998--Photogen, Inc. - a subsidiary of Photogen
Technologies, Inc. (OTC:PHGN) - have been awarded two patents awarded by the
United States Patent and Trademark Office. These patents help position the
company to commercialize its technologies for the treatment of a variety of
diseases.
Patent number 5,829,448 covers methods in photoactivation of molecular
agents. It recognizes Photogen's innovations for the treatment of plant or
animal tissue with two-photon excitation (TPE) of at least one photoactive
molecular agent. Other methods claimed in the patent include the treatment of
cancer in plant or animal tissue, and for the production at least one
photoactivated molecular agent in a particular volume of a material. Not all
of the claimed methods recite simultaneous TPE, however, and some are for
deep tissue photoactivation.
Patent number 5,832,931 covers a method for improved selectivity in
photo-activation and detection of molecular diagnostic agents. It recognizes
that Photogen has a method for the imaging of plant or animal tissue
containing photoactive molecular agents. The method includes treating the
tissue with light sufficient to promote TPE of the photoactive agent. This
process causes the photoactive agent to emit energy that can be detected as a
signal. The present invention also includes a method for imaging of a
particular volume of material containing photoactive molecular agents.
"Recognition for and protection of our intellectual property is a crucial
step towards the validation and subsequent commercialization of our
technology," said John Smolik, president and CEO of Photogen. "Our
activation technology is what sets Photogen apart from other photodynamic
procedures. We continue to evaluate the use of our technology with a
diversity of photoactive agents for a variety of potential applications. Our
most immediate product development goal, however, is to pursue therapies
based on MPE that target diseases of the eye, such as the wet form of macular
degeneration. Gaining these two patents, in many ways, marks the beginning of
a turning point - from research into product development - for the Company."
<PAGE>
Photogen recently announced a research agreement with Massachusetts General
Hospital to evaluate the company's TPE technology as a potential therapy for
age-related macular degeneration. The research will rely directly on the
innovations described in patent number 5,829,448.
The invention was made by Walter G. Fisher, Eric A. Wachter and Craig H.
Dees, all three of whom are principal scientists at Photogen.
About Photogen
Photogen's scientists are working toward the development of proprietary
multi-photon excitation technology to enhance the safety and efficacy of
photodynamic therapy for the diagnosis and treatment of cancer, infectious
diseases and other medical or other conditions. Photogen Technologies, Inc.,
through its wholly owned subsidiary -- Photogen, Inc. -- is a
development-stage Company focused on creating photodynamic-related health
care products based on its proprietary multi-photon excitation and related
technology. The Company has discovered new methods for using laser-generated
light to activate photoactive agents within deep tissue sufficient to produce
a range of beneficial therapeutic and diagnostic outcomes. These technologies
involve methods, materials and devices that may be used to produce light and
photoactive agents that will destroy diseased cells, remove tissue or
identify and diagnose disease.
This news release may contain forward-looking statements that involve risks
and uncertainties. The Company has no products or operating revenues at this
time. A full discussion of the Company's operations and financial condition,
including risk factors that may affect the Company's business and future
prospects, is contained in documents the company files with the Securities
and Exchange Commission, such as the Company's reports on Form 10-QSB, Form
10-KSB and Form 8-K. These documents identify important factors that could
cause the Company's actual performance to differ from current expectations.
The common stock of Photogen Technologies, Inc. is traded on the
over-the-counter bulletin board market under the symbol PHGN.
For information, contact Robert Cathey at Ackermann Public Relations &
Marketing, 423/584-0550, e-mail: [email protected]. Or, visit our World
Wide Web site, at www.photogen.com.
Photogen is a trademark of Photogen Technologies, Inc.
